Monday, November 2, 2026

Commander of U.S. Forces Korea, ‘North Korea’s Priority is the Survival of the Regime’

On November 20th, USFK Commander Paul LaCamera stated that North Korea is prioritizing the preservation of Kim Jong Un's regime.

Unlocking UAE: How Korean Biotech Firms Can Navigate Regulatory Hurdles in 2026

The Ministry of Food and Drug Safety will facilitate communication between local regulatory authorities and Korean bio companies for UAE market entry.

J&J Aims to Treat Cancer Before It Starts Showing Symptoms

Johnson & Johnson leads in multiple myeloma treatment, pioneering early intervention for high-risk patients with a new subcutaneous formulation.

News1

Author's Latest

Is BTGEN the Next Big Player in Biopharmaceuticals? Discover Their Unique CDMO Strategy

BTGEN is expanding its CDMO business with National Growth Fund support, focusing on innovative processes instead of competing on scale.

K-Bio’s Global Leap: How Korea’s Biotech is Shaping Asia’s Innovation Hub

The BIO USA 2026 highlighted Korea's biotech growth, emphasizing the need for increased capital to enhance global competitiveness.

K-Beauty Shines at BIO USA 2026: Discover the Future of Bio-Integrated Skincare!

K-Beauty showcased its biotech innovations at BIO USA 2026 with a pop-up store, attracting global attention and business opportunities.

Samsung Biologics Expands Global Reach: New European Sales Office Set to Boost Biopharmaceuticals Market

Samsung Biologics expands its global sales network with a new office in Europe, aiming for growth in production and portfolio diversification.

Gilead Launches CAR-T Therapy Yescarta in Korea, Offering Fourfold Survival Benefit for Relapsed or Refractory Lymphoma Patients

Yescarta is widely used for second-line treatment in patients with very low survival rates, and should be adopted as a standard treatment in Korea.

ST Pharm Targets Next-Generation RNA Therapies, Positions Itself as Key CDMO Partner at BIO USA

The RNA therapeutics market is evolving, with ST Pharm aiming to lead in precision manufacturing and targeted delivery for next-gen therapies.

“Cheers” in San Diego: K-Biopharma Showcases Growing Global Influence at BIO USA Networking Event

KPBMA supports Korean pharma's global expansion at BIO USA, boosting international interest and partnerships in the biotech sector.

Korean Biopharma Takes Center Stage at BIO USA as Industry Giants and Biotechs Expand Global Reach

The BIO USA 2026 convention gathers over 20,000 bio industry professionals, highlighting the growing presence of Korean companies.

How AI is Revolutionizing Drug Development: Insights from BIO International Convention 2026

The 2026 BIO International Convention focuses on AI, shifting from technology introduction to validating business outcomes.

Dong-A ST Eyes Early-Stage Licensing Deals as Key Growth Strategy, Says VP Oh Yoon-seok [BIO USA]

Dong-A ST aims for global expansion by licensing preclinical drug candidates, focusing on timely execution of R&D strategies by 2027.

Alteogen CEO Says Additional Licensing Deals Near Completion, Highlights Patent Strength [BIO USA]

Alteogen is nearing global licensing deals, focusing on maximizing value and expanding its platform technology in biopharma.

SK Biopharm CEO Lee Dong-hoon: “AI and open innovation are key to drug development” [BIO USA]

SK Biopharmaceuticals focuses on open innovation and AI for drug development, aiming to enhance CNS therapies and expand into new modalities.

Supply Chains, M&A and AI: As China Closes In, K-Bio Faces a Critical Window of Opportunity [BIO USA]

Korea's biotech industry faces challenges and opportunities amid global restructuring, emphasizing AI and support for startups at BIO USA 2026.

Samsung vs. SK Hynix: Who Will Dominate the HBM4E Market in 2026?

Samsung and SK hynix compete in HBM4E semiconductor market, focusing on hybrid bonding and MR-MUF technologies for performance and efficiency.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.